Data from eight patients treated with the combination confirmed these observations, showing an upregulation of PDL1 on non-CD163 expressing immune cells in the tumour, with a loss of CD163+PDL1+ macrophages at the tumour edges [122] but again with no clinical benefit, leading to the abandoning of a planned Phase 2 study. This evidence concerns the gene CD163 and neoplasm.